
Chief Medical Officer, Arcellx @arcellx. Board Member @chordomafdn @rarecancerrf Tweets are my opinions.
Joined November 2013
- Tweets15.3K
- Following2.3K
- Followers3K
- Likes4.7K
Christopher Heery MD retweeted
If youre reading all these headlines about pancreatic cancer and think “nothing like that for mine", hear me out:
Drugs like daraxonrasib are the result of work of 40+ years. Most of prior versions were failing, trials were negative, us GI oncologists left conferences empty handed again.
Your cancer has a version of that. Somewhere there are labs working on the exact fault driving your disease, and right now they're failing at it, because that's what the early part always looks like from the inside.
Unfortunately many people are diagnosed in the years before the answer comes, which is one of the cruellest parts of my job. I receive mails from relatives of died patients who are genuinely happy for patients now, who might benefit from these drugs.
But every disease we can treat properly today was once the one with nothing: Diseases like childhood leukaemia, testicular cancer, some forms of refractory lymphoma or advanced stage melanoma/lung cancer. Until a revolution like immunotherapy, CAR-T cells, any rare targeted drug or like in this case KRAS-inhibitors entered the stage.
Cancer research is unfortunately a marathon, not a sprint, but there will be someone working on your disease trying to create the same post for you one day.
It is still almost unbelievable to read that 5 of 61 patients have had complete remission in stage 4 pancreatic cancer.
We know daraxonrasib works in patients already on treatment, now this small trial looked into patients, who haven't had any treatment yet.
6 in 10 tumors shrank significantly. 5 patients had no detectable cancer left on scans. The median time before the disease progressed was a bit more than 1 year, and >75% of patients were alive at 1 year.
The numbers this replaces: roughly 2 in 10 tumors shrinking, 6 months before progression, about a third alive at 12 months.
Caveats: yes, this is a small trial and we need to wait for the results of the big randomised one with placebo as control, which will report next year, but 2026 really has been a hell of a year for pancreatic cancer patients.
teapaw.org/bbcnewsjapan/status/21…
Christopher Heery MD retweeted
Our @NatureMedicine study of IEC-EC after cilta-cel. This was a true team effort, motivated by our patients, who came to clinic with intractable diarrhea and needed answers. Grateful to be part of this multidisciplinary working group/tumor board.
nature.com/articles/s41591-0…
1/12
Persistent diarrhea after cilta-cel can signal a serious delayed toxicity: immune effector cell-associated enterocolitis (IEC-EC).
Our multicenter @NatureMedicine study characterizes this syndrome and proposes a diagnostic framework. | @fredhutch
nature.com/articles/s41591-0…
Christopher Heery MD retweeted
Team science at its best! Proud of our two Nature Medicine papers published today and the incredible collaboration behind them. Understanding complications is how we make CAR T safer and improve outcomes for patients. Congratulations to both teams! #mmsm @UTMDAnderson Mark Hamilton, @LMikkMD @sharlenedong @FVega957
HTTPS://doi.org/10.1038/s415…
HTTPS://doi.org/10.1038/s415…
Christopher Heery MD retweeted
New blog post on an excursion into potential brachyury-derived epitopes in chordoma; many thanks to @ChrisHeery for the discussion that prompted this.
pirlblog.substack.com/p/brac…
Christopher Heery MD retweeted
Replying to @ChrisHeery @MaverickNY
wait til we can eliminate these in vivo before leukemia develops ...
Christopher Heery MD retweeted
What if we could make CAR-T cells more powerful by simultaneously removing two of their intrinsic inhibitory pathways?
CAR-T therapy has transformed the treatment of hematologic malignancies, but T-cell exhaustion and other negative regulatory mechanisms continue to limit its durability and efficacy.
In a new study, investigators performed a high-throughput in vivo CRISPR double-knockout screen to identify synergistic gene combinations that could enhance T-cell function.
The leading combination was deletion of NR4A1 and SOCS3, two intracellular regulators of T-cell activity.
Several findings stand out:
Enhanced metabolic fitness: Transcriptomic and single-cell analyses revealed increased metabolic pathway activity and mitochondrial function in NR4A1–SOCS3 double-knockout CAR-T cells.
Potent antitumor activity: Engineered T cells demonstrated enhanced tumor control across multiple preclinical tumor models.
Durability: The double-knockout approach supported long-term tumor control, outperforming several established single- and dual-gene engineering strategies.
Safety: The investigators reported preservation of favorable safety features despite enhanced antitumor activity.
The broader significance is the screening strategy itself. Rather than evaluating inhibitory targets individually, systematic in vivo testing of gene combinations may uncover synergistic modifications that would otherwise remain unidentified.
For the next generation of CAR-T therapies, the objective is not simply to increase T-cell activation, but to build cells with the metabolic capacity, functional persistence, and durability needed for sustained tumor control.
NR4A1–SOCS3 dual targeting offers a compelling preclinical example of how combinatorial genome engineering could move CAR-T cells beyond single-checkpoint optimization.
#CART #CRISPR #GeneEditing #CellTherapy #Immunotherapy #CancerResearch
nature.com/articles/s41586-0…
Incredible work and fascinating findings.
How does leukaemia develop? 🩸 How long does it take? ⏳
🌟 Our paper, started back when I was a PhD student in @jrblundell’s lab, is out today in @Nature 🌟
Yearly blood samples from women who developed AML in later life let us trace it back decades 👇
doi.org/10.1038/s41586-026-1…
2
169
Christopher Heery MD retweeted
How does leukaemia develop? 🩸 How long does it take? ⏳
🌟 Our paper, started back when I was a PhD student in @jrblundell’s lab, is out today in @Nature 🌟
Yearly blood samples from women who developed AML in later life let us trace it back decades 👇
doi.org/10.1038/s41586-026-1…
Christopher Heery MD retweeted
1/6
Excited to share my editorial in the #NEJM accompanying the P3 trial of a personalized cancer vaccine in melanoma:
nejm.org/doi/full/10.1056/NE…
A brief ramble:
Christopher Heery MD retweeted
To everyone with cancer who has reached out to @iskander and I about personalized therapeutic cancer vaccines: Your stories are an inspiration. I’m sorry we don’t have something that we know works. I’m sorry the vaccines cost over a hundred thousand dollars outside of trials, and so they aren’t available to everyone. I’m sorry we aren’t moving faster to make them work and make them cheaper. I promise you we are trying, but promises don’t cure cancer. I wish we were smarter, faster, and better. Despite the challenges we are not going to stop.
Christopher Heery MD retweeted
Replying to @BenjaminGVincen
@BenjaminGVincen and I are looking for an bio-savvy engineer who can work on both backend (e.g. storage infra, analysis automation) and frontend (searchable data platform w/ visualization)
Have to know about both sequencing & mass spec data
Apply here: unc.peopleadmin.com/postings…
Christopher Heery MD retweeted
Replying to @iskander
@iskander and I are hiring a senior experimental scientist to work with us on our project funded by Open AI Foundation to discover tumor antigens, tumor antigen-associated T cell receptors, and assess TCR performance via functional studies of TCR-engineered T cells. Apply here ( unc.peopleadmin.com/postings… ) if interested!
Christopher Heery MD retweeted
We’re thrilled to announce a new joint grants program with @TheMarkFdn offering awards of up to $500K to help pave the way for chordoma patients to benefit from emerging treatment approaches that target cell surface proteins or peptides presented by MHC molecules on cancer cells. This is a major area of opportunity that builds on the results of several projects we’ve supported in recent years to identify surface targets.
Researchers: the request for proposals will open on Monday, October 26. More info: chordomafoundation.org/resea…
You just know @united is salivating at this.
When artist feels the music! She plays with her body and soul. She inspires the entire orchestra. Her style is truly unique.
1
1
293
Christopher Heery MD retweeted
1/ We discovered something totally unexpected about the neural structure of consciousness that overturns decades of thinking on its biological basis and brings us significantly closer to the recipe for generating conscious awareness.
New preprint: biorxiv.org/content/10.64898… (led by @HesseJanis, with @FrankLanfranchi, @_conor_mcgrory, @Yuelin_Shi, and @EngelTatiana)
Christopher Heery MD retweeted
In-vivo CAR-T is the rage and it may work, but it is not clear it has the durability or long-term efficacy of ex-vivo. In general, I bet ex vivo in multiple applications will get cheaper and will win in some big verticals.
Big pharma committed about $6.6 billion to in vivo CAR-T in roughly seven months last year.
@abbvie bought @capstantx for $2.1B. @AstraZeneca bought EsoBiotec for up to $1B. @bmsnews paid $1.5B for Orbital. @KitePharma picked up Interius for $350M.
EsoBiotec and Interius both run on lentiviral vectors. So does @UmojaBiopharma, which AbbVie partnered with before buying Capstan.
Which is why today's news from @AsimovBio and @LonzaGroup caught my attention.
In ex vivo cell therapy, the lentivirus is a tool. You use it in a lab to engineer a patient's cells and you're done with it. In vivo flips that. The vector goes into the patient. As @alectricity put it, the vector becomes the drug.
That makes manufacturing the hard part. Most lentivirus is still made by transfecting cells with multiple plasmids, batch after batch. It's expensive, variable, and tough to scale.
Asimov's LV Edge Producer lines build all the lentiviral genes into the host cell itself. No transient transfection, no GMP plasmid bill, and titers above 1E9 TU/mL for CAR constructs, about 10x what they saw before.
Lonza brings the process development, analytics, scale-up and GMP manufacturing. Putting the two together at the cell line stage means manufacturability gets designed in early, before a program hits scale-up and finds out the hard way.
If in vivo CAR-T works the way pharma is betting, the bottleneck moves to making enough clean, consistent vector at a cost that works for big indications. That's the problem this collaboration is going after.
Alec first spoke at @SynBioBeta in 2018, back when Asimov was a genetic circuits startup. Soren Flygenring Basset from Lonza joined us on stage in San Jose this May. Fun to see these two worlds connect.
Congrats to @alectricity, Imroz Ghangas and the @AsimovBio team, and to Daniel Palmacci, Thomas Fellner and Soren at @LonzaGroup.
Christopher Heery MD retweeted
Read the full study in Nature Biomedical Engineering: nature.com/articles/s41551-0…
This is a story worth following. Anyone with more information, please share.
Two bacteria, injected into the bloodstream of mice, wiped out tumors without help from the immune system. A new study shows how they do it, and the mechanism is not what most people would expect.
Researchers at the Japan Advanced Institute of Science and Technology, with the University of Tsukuba and Daiichi Sankyo, tested a pair of naturally occurring bacteria called AUN. One is Proteus mirabilis (called A-gyo), isolated from inside a tumor. The other is Rhodopseudomonas palustris (called UN-gyo), a purple photosynthetic bacterium. No genetic engineering was used.
The idea of using bacteria against cancer is old. In the 1890s, William Coley noticed that some patients improved after infections and began injecting bacteria on purpose. Most modern versions still depend on the immune system to finish the job.
That is a problem.
Chemotherapy and radiation suppress immunity, and solid tumors have a low-oxygen core (hypoxia) that immune cells struggle to enter.
Checkpoint inhibitors and CAR T cells, the newer immunotherapies, also rely on those immune cells.
This study asked whether bacteria could kill tumors on their own.
Key findings:
• Tumors disappeared completely in the treated mice, and the mice lived longer. This held in mice with normal immune systems, mice with weakened immune systems, and mice carrying human tumors
• The mice showed no visible signs of toxicity. There was also no cytokine storm, a dangerous overreaction where the immune system floods the body with inflammation, which is a known risk with some cancer immunotherapies
• The two bacteria were mixed at about 3 parts A-gyo to 97 parts UN-gyo. In the lab, they settled back into that same balance within a week, even when researchers started them at very different ratios
• Inside tumors, the balance reportedly flips to about 99 parts A-gyo to 1 part UN-gyo, according to the institute's press release
• A-gyo was missing the genes for the sticky surface structures bacteria normally use to attach to tissue and cause infection. That likely makes it less harmful than its commercial cousin
• Treated tumors were full of blood clots and showed widespread tissue death
So this is what seems to be happening from mechanistic angle:
First, the bacteria reach the tumor. Tumors are a hospitable place for bacteria. They have low oxygen, leaky blood vessels, and a suppressed local immune response. The bacteria grow there, form biofilms (sticky bacterial communities), and also kill cancer cells directly.
Second, they trigger clotting inside the tumor. Cytokines (inflammatory signaling proteins) rise, platelets aggregate, and fibrin (the protein mesh in blood clots) builds up. This is thrombosis, the formation of clots within vessels.
Third, the vessels collapse. Think of cutting the water supply to a building. A tumor needs a dense network of new blood vessels to bring in oxygen and nutrients. Clot them off, and the tissue behind them starves and dies.
The partnership also appears to act as a safety system. UN-gyo dampens A-gyo's pathogenicity, reduces its ability to rupture red blood cells (hemolysis), and helps push A-gyo into a long, filament-like form in the presence of cancer metabolites. In other words, the second bacterium keeps the first one in check outside the tumor.
Big caveats, though.
This was all done in mice. Mouse tumors, mouse blood clotting, and mouse immune responses differ from ours, and complete remission in mice has a poor track record of translating to people. Injecting live bacteria into the blood, in people who may already be sick, carries infection risks that mouse studies can't fully capture. The same clotting mechanism that destroys tumors could be dangerous if it occurred outside them. And the study was led by a group that is preparing to launch a startup, which is worth keeping in mind when reading the safety claims.
This is, however, a new way to think about cancer, one of the leading causes of death in older adults. The rate of cancer rises steeply after 50, and most current treatments depend on an immune system that also weakens with age and with treatment. A therapy that works without immune cells would matter most for exactly the people who need it most.
The broader point is that the tumor itself is an ecosystem, and bacteria that live there may be turned into a tool. Whether that tool is safe enough for people is the question that remains.
2
280
Christopher Heery MD retweeted
Two bacteria, injected into the bloodstream of mice, wiped out tumors without help from the immune system. A new study shows how they do it, and the mechanism is not what most people would expect.
Researchers at the Japan Advanced Institute of Science and Technology, with the University of Tsukuba and Daiichi Sankyo, tested a pair of naturally occurring bacteria called AUN. One is Proteus mirabilis (called A-gyo), isolated from inside a tumor. The other is Rhodopseudomonas palustris (called UN-gyo), a purple photosynthetic bacterium. No genetic engineering was used.
The idea of using bacteria against cancer is old. In the 1890s, William Coley noticed that some patients improved after infections and began injecting bacteria on purpose. Most modern versions still depend on the immune system to finish the job.
That is a problem.
Chemotherapy and radiation suppress immunity, and solid tumors have a low-oxygen core (hypoxia) that immune cells struggle to enter.
Checkpoint inhibitors and CAR T cells, the newer immunotherapies, also rely on those immune cells.
This study asked whether bacteria could kill tumors on their own.
Key findings:
• Tumors disappeared completely in the treated mice, and the mice lived longer. This held in mice with normal immune systems, mice with weakened immune systems, and mice carrying human tumors
• The mice showed no visible signs of toxicity. There was also no cytokine storm, a dangerous overreaction where the immune system floods the body with inflammation, which is a known risk with some cancer immunotherapies
• The two bacteria were mixed at about 3 parts A-gyo to 97 parts UN-gyo. In the lab, they settled back into that same balance within a week, even when researchers started them at very different ratios
• Inside tumors, the balance reportedly flips to about 99 parts A-gyo to 1 part UN-gyo, according to the institute's press release
• A-gyo was missing the genes for the sticky surface structures bacteria normally use to attach to tissue and cause infection. That likely makes it less harmful than its commercial cousin
• Treated tumors were full of blood clots and showed widespread tissue death
So this is what seems to be happening from mechanistic angle:
First, the bacteria reach the tumor. Tumors are a hospitable place for bacteria. They have low oxygen, leaky blood vessels, and a suppressed local immune response. The bacteria grow there, form biofilms (sticky bacterial communities), and also kill cancer cells directly.
Second, they trigger clotting inside the tumor. Cytokines (inflammatory signaling proteins) rise, platelets aggregate, and fibrin (the protein mesh in blood clots) builds up. This is thrombosis, the formation of clots within vessels.
Third, the vessels collapse. Think of cutting the water supply to a building. A tumor needs a dense network of new blood vessels to bring in oxygen and nutrients. Clot them off, and the tissue behind them starves and dies.
The partnership also appears to act as a safety system. UN-gyo dampens A-gyo's pathogenicity, reduces its ability to rupture red blood cells (hemolysis), and helps push A-gyo into a long, filament-like form in the presence of cancer metabolites. In other words, the second bacterium keeps the first one in check outside the tumor.
Big caveats, though.
This was all done in mice. Mouse tumors, mouse blood clotting, and mouse immune responses differ from ours, and complete remission in mice has a poor track record of translating to people. Injecting live bacteria into the blood, in people who may already be sick, carries infection risks that mouse studies can't fully capture. The same clotting mechanism that destroys tumors could be dangerous if it occurred outside them. And the study was led by a group that is preparing to launch a startup, which is worth keeping in mind when reading the safety claims.
This is, however, a new way to think about cancer, one of the leading causes of death in older adults. The rate of cancer rises steeply after 50, and most current treatments depend on an immune system that also weakens with age and with treatment. A therapy that works without immune cells would matter most for exactly the people who need it most.
The broader point is that the tumor itself is an ecosystem, and bacteria that live there may be turned into a tool. Whether that tool is safe enough for people is the question that remains.





















